{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:30:02Z","timestamp":1765269002475},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12895-2","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:26:52Z","timestamp":1727170012000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical significance of intensity-modulated radiotherapy (IMRT) to the distant metastatic lymph nodes for metastatic cervical cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Chi","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"issue":"5","key":"12895_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Clinical applications of circulating Tumor cells and circulating tumor DNA as Liquid Biopsy. Cancer Discov. 2016;6(5):479\u201391.","journal-title":"Cancer Discov"},{"issue":"3","key":"12895_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12895_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1186\/s12889-021-11401-8","volume":"21","author":"M Guo","year":"2021","unstructured":"Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and joinpoint analysis. BMC Public Health. 2021;21(1):1329.","journal-title":"BMC Public Health"},{"issue":"4","key":"12895_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.semradonc.2020.05.003","volume":"30","author":"CH Feng","year":"2020","unstructured":"Feng CH, et al. Immunotherapy with Radiotherapy and Chemoradiotherapy for Cervical Cancer. Semin Radiat Oncol. 2020;30(4):273\u201380.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"12895_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajog.2015.07.022","volume":"214","author":"KS Pfaendler","year":"2016","unstructured":"Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22\u201330.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"12895_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"12895_CR7","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.3802\/jgo.2016.27.e16","volume":"27","author":"R Kobayashi","year":"2016","unstructured":"Kobayashi R, et al. Details of recurrence sites after definitive radiation therapy for cervical cancer. J Gynecol Oncol. 2016;27(2):e16.","journal-title":"J Gynecol Oncol"},{"issue":"5","key":"12895_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00404-017-4520-8","volume":"296","author":"M Kozaki","year":"2017","unstructured":"Kozaki M, et al. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy. Arch Gynecol Obstet. 2017;296(5):997\u20131003.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"12895_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","volume":"17","author":"WJ Koh","year":"2019","unstructured":"Koh WJ, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64\u201384.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"12895_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.radonc.2018.03.003","volume":"127","author":"D Cibula","year":"2018","unstructured":"Cibula D, et al. The European Society of Gynaecological Oncology\/European Society for Radiotherapy and Oncology\/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;127(3):404\u201316.","journal-title":"Radiother Oncol"},{"issue":"1","key":"12895_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2012.12.035","volume":"129","author":"CA Leath","year":"2013","unstructured":"Leath CA 3rd and, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol. 2013;129(1):251\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"12895_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1634\/theoncologist.2012-0367","volume":"18","author":"R Mazeron","year":"2013","unstructured":"Mazeron R, et al. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist. 2013;18(4):415\u201322.","journal-title":"Oncologist"},{"issue":"4","key":"12895_CR13","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.3802\/jgo.2016.27.e43","volume":"27","author":"H Li","year":"2016","unstructured":"Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43.","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"12895_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.clon.2021.06.007","volume":"33","author":"CE Shelley","year":"2021","unstructured":"Shelley CE, et al. Adaptive Radiotherapy in the management of Cervical Cancer: review of strategies and clinical implementation. Clin Oncol (R Coll Radiol). 2021;33(9):579\u201390.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"12895_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijrobp.2004.06.207","volume":"61","author":"AK Singh","year":"2005","unstructured":"Singh AK, et al. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys. 2005;61(2):450\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"12895_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijrobp.2007.09.042","volume":"71","author":"W Small Jr","year":"2008","unstructured":"Small W Jr., et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):428\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"12895_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","volume":"3","author":"P Bonomi","year":"1985","unstructured":"Bonomi P, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3(8):1079\u201385.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12895_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/18715206113136660372","volume":"14","author":"H van Meir","year":"2014","unstructured":"van Meir H, et al. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med Chem. 2014;14(2):190\u2013203.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"12895_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12905-024-03100-4","volume":"24","author":"F Ferrari","year":"2024","unstructured":"Ferrari F, Giannini A. Approaches to prevention of gynecological malignancies. BMC Womens Health. 2024;24(1):254.","journal-title":"BMC Womens Health"},{"issue":"2","key":"12895_CR20","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.suronc.2011.12.008","volume":"21","author":"M Peiretti","year":"2012","unstructured":"Peiretti M, et al. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012;21(2):e59\u201366.","journal-title":"Surg Oncol"},{"issue":"11","key":"12895_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/jog.13446","volume":"43","author":"M Okazawa-Sakai","year":"2017","unstructured":"Okazawa-Sakai M, et al. Predictors of distant relapse in patients with FIGO stage IIB-IVA cervical cancer treated with definitive radiotherapy. J Obstet Gynaecol Res. 2017;43(11):1743\u201350.","journal-title":"J Obstet Gynaecol Res"},{"issue":"28","key":"12895_CR22","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649\u201355.","journal-title":"J Clin Oncol"},{"issue":"15","key":"12895_CR23","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","volume":"22","author":"DH Moore","year":"2004","unstructured":"Moore DH, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12895_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ygyno.2009.07.024","volume":"115","author":"JV Fiorica","year":"2009","unstructured":"Fiorica JV, et al. A phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115(2):285\u20139.","journal-title":"Gynecol Oncol"},{"issue":"10103","key":"12895_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654\u201363.","journal-title":"Lancet"},{"issue":"7","key":"12895_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27(7):1069\u201374.","journal-title":"J Clin Oncol"},{"issue":"20","key":"12895_CR27","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, et al. Pembrolizumab for Persistent, recurrent, or metastatic cervical Cancer. N Engl J Med. 2021;385(20):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"12895_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14656566.2023.2298329","volume":"25","author":"O D\u2019Oria","year":"2024","unstructured":"D\u2019Oria O, et al. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature. Expert Opin Pharmacother. 2024;25(1):55\u201365.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"12895_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609\u201319.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12895-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:26:55Z","timestamp":1727170015000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12895"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12895-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center, Shanghai, China. Informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1170"}}